GlassScriptPhysician profile
Shin W Kang
NPI 1457411209
$4,695.63
in general payments reported to CMS, 2019-2025
26 companies · $260 in 2025
The $260 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $951 · 2020: $648 · 2021: $881 · 2022: $954 · 2023: $392 · 2024: $609 · 2025: $260.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,261.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,261.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $984.80 | 2019-2024 | |
| Amarin Pharma, INC. | $811.57 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $425.25 | 2019-2024 | Farxiga, Airsupra |
| Lilly USA, LLC | $406.29 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $325.16 | 2019-2025 | Repatha, Otezla |
| Nestle Healthcare Nutrition INC. | $323.07 | 2021-2023 | |
| Pfizer INC. | $226.65 | 2019-2020 | |
| Gilead Sciences, INC. | $215.73 | 2019-2023 | |
| Novo Nordisk INC | $145.19 | 2021-2024 | Ozempic |
| Bayer Healthcare Pharmaceuticals INC. | $138.57 | 2024-2025 | |
| Aimmune Therapeutics, INC. | $138.40 | 2024-2025 | Zenpep |
| Novartis Pharmaceuticals Corporation | $99.64 | 2021-2025 | |
| Vivus LLC | $92.64 | 2021-2025 | Pancreaze |
| E.R. Squibb & Sons, L.L.C. | $64.68 | 2022 | |
| Glaxosmithkline, LLC. | $37.74 | 2024-2025 | Arexvy, Shingrix, Trelegy Ellipta |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $34.48 | 2019 | |
| Shield Therapeutics INC | $33.37 | 2024 | |
| Radius Health, INC. | $29.93 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.33 | 2021 | |
| Janssen Pharmaceuticals, INC | $23.54 | 2020 | |
| Ironwood Pharmaceuticals, INC | $22.86 | 2022 | |
| Exact Sciences Corporation | $21.94 | 2024 | Cologuard Collection Kit |
| Boston Scientific Corporation | $19.16 | 2020 | |
| Otsuka America Pharmaceutical, INC. | $17.14 | 2024 | Rexulti |
| Esperion Therapeutics, INC. | $16.70 | 2021 | |
| Almatica Pharma LLC | $15.80 | 2025 | Loreev Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shin Kang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.